AVEO/Astellas seek US FDA nod for tivozanib in advanced RCC
This article was originally published in Scrip
Executive Summary
AVEO Oncology and Astellas Pharma are seeking the US FDA's blessing to market the firms' oral tyrosine kinase inhibitor tivozanib to treat patients with advanced renal cell carcinoma (RCC). Tivozanib is designed to target the vascular endothelial growth factor (VEGF) pathway, a clinically validated target in RCC and other solid tumors.